Detail akcie Emergent Bio online

Business Summary: Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Emergent Biosolutions Inc revenues decreased 6% to $1.05B. Net loss increased from $211.6M to $760.5M. Revenues reflect MCM Products segment decrease of 23% to $447.2M, Services segment decrease of 29% to $78.5M, U.S.Government segment decrease of 18% to $394.7M. Higher net loss reflects Goodwill impairment increase from $6.7M to $218.2M (expense).